Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 open-label ASP8374 monotherapy in Japanese patients with advanced solid tumors
jRCT2080224693Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- May 2019
- Modality
- Vaccines & Immunotherapeutics, IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASP8374 in Non-hematologic malignancy (2 arms), sponsored by Astellas Pharma. Primary endpoints: Dose-limiting toxicities and Tolerability. Started May 2019; status: completed.
02
Drugs
ASP8374
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on jRCT2080224693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224693.